Clinical Trials Directory

Trials / Completed

CompletedNCT01254318

Assessment of the Fungal Infection Incidence Across Canada for High Risk Participants With Hematological Disease (P07501)

Temporal Realistic Assessment of the Fungal Infection Incidence Across Canada for High Risk Subjects With Hematological Disease (TRAFIC)

Status
Completed
Phase
Study type
Observational
Enrollment
130 (actual)
Sponsor
Merck Sharp & Dohme LLC · Industry
Sex
All
Age
Healthy volunteers
Not accepted

Summary

This will be a retrospective study that includes retrospective chart reviews at major institutions across Canada. The intent of the study is to generate both regional and national incidence data for non-Candida invasive fungal infections (IFI) in high risk participants. The study will include participants receiving stem cell transplant and high dose chemotherapy treatment for leukemia.

Conditions

Interventions

TypeNameDescription
OTHERStandard CareHealth-care interventions will be recorded; no additional procedures outside the standard of care will be required.

Timeline

Start date
2013-03-01
Primary completion
2014-11-01
Completion
2014-11-01
First posted
2010-12-06
Last updated
2016-11-02
Results posted
2016-11-02

Source: ClinicalTrials.gov record NCT01254318. Inclusion in this directory is not an endorsement.

Assessment of the Fungal Infection Incidence Across Canada for High Risk Participants With Hematological Disease (P07501 (NCT01254318) · Clinical Trials Directory